[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0309711A - Método para o tratamento de doenças do câncer - Google Patents

Método para o tratamento de doenças do câncer

Info

Publication number
BR0309711A
BR0309711A BR0309711-0A BR0309711A BR0309711A BR 0309711 A BR0309711 A BR 0309711A BR 0309711 A BR0309711 A BR 0309711A BR 0309711 A BR0309711 A BR 0309711A
Authority
BR
Brazil
Prior art keywords
progressing
radiotherapy
cancer
treatment
treating cancer
Prior art date
Application number
BR0309711-0A
Other languages
English (en)
Inventor
John David Rothermel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0309711A publication Critical patent/BR0309711A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silicon Polymers (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

"MéTODO PARA O TRATAMENTO DE DOENçAS DO CâNCER". A presente invenção refere-se a um método para o tratamento de um animal de sangue quente, de modo especial de um ser humano que tenha uma doença de câncer selecionada a partir de heptoma, câncer primário do tubo falopiano, câncer primário do peritónio; câncer da mama em progresso depois de tratamento com agentes hormonais ou radioterapia; carcinoma da célula renal em progresso depois do tratamento com uma citocina, radioterapia e/ou nefrectomia; melanoma em progresso depois do tratamento com radioterapia, câncer da próstata em progresso depois de orquiectomia; câncer de ovário em progresso depois do tratamento com um composto de platina ou radioterapia; e câncer de coloretal depois de radioterapia e/ou tratamento com oxaplatina ou irinotecan; e a metástase dos mesmos, que compreende a administração ao referido animal de uma quantidade terapeuticamente eficaz de um derivado da epotilona da fórmula I
BR0309711-0A 2002-05-01 2003-04-30 Método para o tratamento de doenças do câncer BR0309711A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37706302P 2002-05-01 2002-05-01
PCT/EP2003/004581 WO2003092683A1 (en) 2002-05-01 2003-04-30 Epothilone derivative for the treatment of hepatoma and other cancer diseases

Publications (1)

Publication Number Publication Date
BR0309711A true BR0309711A (pt) 2005-02-09

Family

ID=29401440

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309711-0A BR0309711A (pt) 2002-05-01 2003-04-30 Método para o tratamento de doenças do câncer

Country Status (24)

Country Link
US (2) US20050282873A1 (pt)
EP (1) EP1503756B1 (pt)
JP (1) JP2005528414A (pt)
KR (1) KR20040106422A (pt)
CN (1) CN1649585A (pt)
AT (1) ATE439130T1 (pt)
AU (1) AU2003227702B2 (pt)
BR (1) BR0309711A (pt)
CA (1) CA2483826C (pt)
CY (1) CY1109607T1 (pt)
DE (1) DE60328772D1 (pt)
DK (1) DK1503756T3 (pt)
ES (1) ES2330324T3 (pt)
HK (1) HK1073601A1 (pt)
IL (1) IL164783A (pt)
MX (1) MXPA04010853A (pt)
NO (1) NO20045249L (pt)
NZ (1) NZ536178A (pt)
PL (1) PL211114B1 (pt)
PT (1) PT1503756E (pt)
RU (1) RU2358730C2 (pt)
SI (1) SI1503756T1 (pt)
WO (1) WO2003092683A1 (pt)
ZA (1) ZA200408492B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0309711A (pt) * 2002-05-01 2005-02-09 Novartis Ag Método para o tratamento de doenças do câncer
US20060235059A1 (en) * 2003-09-02 2006-10-19 Dilea Clifford Cancer treatment with epothilones
US8394365B2 (en) * 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
CA2597647A1 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
MX2012013100A (es) 2010-05-18 2013-01-22 Cerulean Pharma Inc Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
BR0008379A (pt) * 1999-02-22 2002-09-24 Biotechnolog Forschung Gmbh Epotilonas modificadas em c-21
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
BR0309711A (pt) * 2002-05-01 2005-02-09 Novartis Ag Método para o tratamento de doenças do câncer

Also Published As

Publication number Publication date
RU2358730C2 (ru) 2009-06-20
US20080161369A1 (en) 2008-07-03
PL371727A1 (en) 2005-06-27
PT1503756E (pt) 2009-10-28
NO20045249L (no) 2005-01-26
CN1649585A (zh) 2005-08-03
ES2330324T3 (es) 2009-12-09
RU2004135307A (ru) 2005-09-10
SI1503756T1 (sl) 2010-01-29
NZ536178A (en) 2007-10-26
HK1073601A1 (en) 2005-10-14
ATE439130T1 (de) 2009-08-15
EP1503756B1 (en) 2009-08-12
US20050282873A1 (en) 2005-12-22
ZA200408492B (en) 2006-09-27
AU2003227702B2 (en) 2007-07-26
DE60328772D1 (de) 2009-09-24
JP2005528414A (ja) 2005-09-22
CA2483826A1 (en) 2003-11-13
MXPA04010853A (es) 2005-02-14
CY1109607T1 (el) 2014-08-13
IL164783A0 (en) 2005-12-18
WO2003092683A1 (en) 2003-11-13
DK1503756T3 (da) 2009-11-16
KR20040106422A (ko) 2004-12-17
EP1503756A1 (en) 2005-02-09
IL164783A (en) 2011-08-31
PL211114B1 (pl) 2012-04-30
AU2003227702A1 (en) 2003-11-17
CA2483826C (en) 2012-04-17

Similar Documents

Publication Publication Date Title
CY1109607T1 (el) Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
EA201201154A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
RU2012140185A (ru) Ингибирование ангиогенеза
PH12019502586A1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
RU2014108042A (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
EA201290062A1 (ru) Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
NZ603303A (en) Peptide epoxyketones for proteasome inhibition
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
DE602005026508D1 (de) Monozyklische heterozyklen als kinase-hemmer
RU2008150250A (ru) Способ лечения рака
EA201170344A1 (ru) Азаиндольные ингибиторы iap
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
ATE424208T1 (de) Proteinkinaseinhibitoren
DE602005015304D1 (de) Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer
ATE461713T1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
TW200724158A (en) Combination therapy in the treatment of cancer
TW200732305A (en) Cancer chemotherapy
TW200724137A (en) Cancer treatment
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
ATE400268T1 (de) Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
DE10344882A1 (de) Neue Makrocyclen zur Behandlung von Krebserkrankungen
TN2009000427A1 (en) Use of hdac inhibitors for the treatment of gastrointestinal cancers

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI